Citation Impact
Citing Papers
Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza
2006
DNA methylation arrays as surrogate measures of cell mixture distribution
2012 Standout
Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice
2021 StandoutNobel
Improving pandemic H5N1 influenza vaccines by combining different vaccine platforms
2014
Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine
2009
Serogroup B meningococcal vaccines—an unfinished story
2010
Pandemic Influenza Vaccines
2009
Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults
2007 Standout
Effect of Immunosuppression on T-Helper 2 and B-Cell Responses to Influenza Vaccination
2015 StandoutNobel
Safety Review: Squalene and Thimerosal in Vaccines
2010
Immune modulation by bacterial outer membrane vesicles
2015
Development of Effective Vaccines against Pandemic Influenza
2006
Intranasal c-di-GMP-adjuvanted plant-derived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice
2011
Vaccines for Seasonal and Pandemic Influenza
2006
Influenza Vaccines for the Future
2010
Extracellular Vesicle RNA: A Universal Mediator of Microbial Communication?
2018 StandoutNobel
Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia
2006 Standout
MF59 Emulsion Is an Effective Delivery System for a Synthetic TLR4 Agonist (E6020)
2009
Effects of Adjuvants on the Safety and Immunogenicity of an Avian Influenza H5N1 Vaccine in Adults
2008
Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza Preparedness
2008 Standout
Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer
2011
A Live Attenuated Influenza A(H5N1) Vaccine Induces Long-Term Immunity in the Absence of a Primary Antibody Response
2014
A Burkholderia pseudomallei Outer Membrane Vesicle Vaccine Provides Protection against Lethal Sepsis
2014
A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses
2010
Superior immunogenicity of HCV envelope glycoproteins when adjuvanted with cyclic-di-AMP, a STING activator or archaeosomes
2017 StandoutNobel
Avian Influenza Virus Infections in Humans
2006
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis
2014 Standout
Improved protection against avian influenza H5N1 virus by a single vaccination with virus-like particles in skin using microneedles
2010
From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak
2011
MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile
2003
Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults
2010
The annual impact of seasonal influenza in the US: Measuring disease burden and costs
2007 Standout
Influenza vaccine: The challenge of antigenic drift
2007
Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge
2007
Influenza
2003
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice
2020 StandoutNobel
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma
2011
Coronavirus envelope protein: current knowledge
2019 Standout
Synthetic Double-Stranded RNAs Are Adjuvants for the Induction of T Helper 1 and Humoral Immune Responses to Human Papillomavirus in Rhesus Macaques
2009 StandoutNobel
Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment
2008
The cytokine storm of severe influenza and development of immunomodulatory therapy
2015 Standout
Vaccine adjuvants – understanding molecular mechanisms to improve vaccines
2014 StandoutNobel
Intradermal influenza vaccine and new devices: a promising chance for vaccine improvement
2011
Safety and immunogenicity of whole-virus, alum-adjuvanted whole-virus, virosomal, and whole-virus intradermal influenza A/H9N2 vaccine formulations
2009
A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T‐cell immunity in vivo
2011 StandoutNobel
Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis
2009
Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine
2014
The effect of peripheral blood values on prognosis of patients with locally advanced gastric cancer before treatment
2009
Computational design of trimeric influenza-neutralizing proteins targeting the hemagglutinin receptor binding site
2017 StandoutNobel
A Clinical Trial of a Whole-Virus H5N1 Vaccine Derived from Cell Culture
2008
Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study
2009
MF59®-Adjuvanted H5N1 Vaccine Induces Immunologic Memory and Heterotypic Antibody Responses in Non-Elderly and Elderly Adults
2009
Safety and Immunogenicity of a Recombinant Parvovirus B19 Vaccine Formulated with MF59C.1
2003
Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults
2008
Antibody Persistence after 2‐Dose Priming and Booster Response to a Third Dose of an Inactivated, Adjuvanted, Whole‐Virion H5N1 Vaccine
2008
Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults
2010 StandoutNobel
Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming Strategy
2005
Strategies for mitigating an influenza pandemic
2006 StandoutNature
Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial
2006
Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein
2005
Pre-treatment white blood cell subtypes as prognostic indicators in ovarian cancer
2007
Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations
2006
Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults
2009
Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions
2015 Standout
The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
2013 Standout
Influenza vaccine immunology
2010
Classification, Functions, and Clinical Relevance of Extracellular Vesicles
2012 Standout
A Computationally Designed Hemagglutinin Stem-Binding Protein Provides In Vivo Protection from Influenza Independent of a Host Immune Response
2016 StandoutNobel
Microneedles for drug and vaccine delivery
2012 Standout
High neutrophil-to-lymphocyte ratio is an independent marker of poor disease-specific survival in patients with oral cancer
2013
Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies
2018 StandoutNobel
Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection
2009
Parvovirus B19
2004 Standout
Safety and Immunogenicity of an Inactivated Influenza A/H5N1 Vaccine Given with or without Aluminum Hydroxide to Healthy Adults: Results of a Phase I–II Randomized Clinical Trial
2008
SARS-CoV-2 vaccines in development
2020 StandoutNature
Inflammasomes in health and disease
2012 StandoutNature
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
2013 Standout
Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups
2020
Newcastle Disease Virus Expressing a Dendritic Cell-Targeted HIV Gag Protein Induces a Potent Gag-Specific Immune Response in Mice
2010 StandoutNobel
Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010.
2009 Standout
Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine
2009
Immunization of Primates with a Newcastle Disease Virus-Vectored Vaccine via the Respiratory Tract Induces a High Titer of Serum Neutralizing Antibodies against Highly Pathogenic Avian Influenza Virus
2007
Pretreatment Neutrophil-to-Lymphocyte Ratio as an Independent Predictor of Recurrence in Patients With Nonmetastatic Renal Cell Carcinoma
2010
The New “Face” of CHEST Heralds a New Era
2006 Standout
Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?
2019 Standout
Molecular and cellular signatures of human vaccine adjuvants
2008
Cyclic di-GMP: the First 25 Years of a Universal Bacterial Second Messenger
2013 Standout
Intranasal Vaccination with 1918 Influenza Virus-Like Particles Protects Mice and Ferrets from Lethal 1918 and H5N1 Influenza Virus Challenge
2009
Hepatitis C virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses
2006 StandoutNobel
Systematic review and economic decision modelling for the prevention and treatment of influenza A and B
2003
Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi
2015 Standout
Microneedle Delivery of H5N1 Influenza Virus-Like Particles to the Skin Induces Long-Lasting B- and T-Cell Responses in Mice
2010
CD4 T Cell Help Is Limiting and Selective during the Primary B Cell Response to Influenza Virus Infection
2013
Immunogenicity and Safety of MF59-Adjuvanted H5N1 Influenza Vaccine From Infancy to Adolescence
2010
Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59
2011
Proteomic Analysis and Immunogenicity of Mannheimia haemolytica Vesicles
2012
Avian Influenza A (H5N1) Infection in Humans
2005
Chemically Modified Bacterial Sacculi as a Vaccine Microparticle Scaffold
2022 StandoutNobel
Biogenesis of Outer Membrane Vesicles in Serratia marcescens Is Thermoregulated and Can Be Induced by Activation of the Rcs Phosphorelay System
2012
Influenza A Virus Lacking M2 Protein as a Live Attenuated Vaccine
2009
Adjuvanted H5N1 vaccine induces early CD4+T cell response that predicts long-term persistence of protective antibody levels
2009
Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines
2007
The microbial mimic poly IC induces durable and protective CD4+T cell immunity together with a dendritic cell targeted vaccine
2008 StandoutNobel
Nanoparticle vaccines
2013
Works of Ellen Ypma being referenced
The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans
2011
Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza
2001
Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population
2003
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials
2013
Lymphocyte Counts Independently Predict Overall Survival in Advanced Cancer Patients: A Biomarker for IL-2 Immunotherapy
2003
Immunogenicity and Tolerability in Infants of a New Zealand Epidemic Strain Meningococcal B Outer Membrane Vesicle Vaccine
2009
Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand
2007